{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:19:06Z","timestamp":1792606746353,"version":"4.5.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/mjt.0b013e3181d169b5","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T08:15:25Z","timestamp":1269418525000},"page":"566-576","source":"Crossref","is-referenced-by-count":27,"title":["A Long-Term, Open-Label Study to Confirm the Safety of Topical Diclofenac Solution Containing Dimethyl Sulfoxide in the Treatment of the Osteoarthritic Knee"],"prefix":"10.1097","volume":"17","author":[{"given":"J Zev","family":"Shainhouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Grierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Naseer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210202","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update.","volume":"43","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","article-title":"EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).","volume":"62","author":"Jordan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R3-6-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.","volume":"16","author":"Zhang","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"R4-6-20210202","first-page":"140","article-title":"An evidenced-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference.","volume":"33","author":"Tannenbaum","year":"2006","journal-title":"J Rheumatol"},{"key":"R7-6-20210202","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/ard.2003.020313","article-title":"Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.","volume":"63","author":"Pincus","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R8-6-20210202","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/archinte.167.4.394","article-title":"Frequency of analgesic use and risk of hypertension among men.","volume":"167","author":"Forman","year":"2007","journal-title":"Arch Intern Med"},{"key":"R9-6-20210202","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.105.595793","article-title":"Nonsteroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events.","volume":"113","author":"Chan","year":"2006","journal-title":"Circulation"},{"key":"R10-6-20210202","first-page":"CD004257","article-title":"Acetaminophen for osteoarthritis.","volume":"1","author":"Towheed","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-6-20210202","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11926-007-0020-3","article-title":"Cardiovascular risk, hypertension, and NSAIDs.","volume":"9","author":"White","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"R13-6-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2474-8-73","article-title":"Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.","volume":"8","author":"Moore","year":"2007","journal-title":"BMC Musculoskelet Disord"},{"key":"R14-6-20210202","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bmj.331.7528.1310","article-title":"Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.","volume":"331","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"R15-6-20210202","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials.","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"R16-6-20210202","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.rdc.2008.03.006","article-title":"Topical agents in the treatment of rheumatic pain.","volume":"34","author":"Moore","year":"2008","journal-title":"Rheum Dis Clin N Am"},{"key":"R17-6-20210202","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1503\/cmaj.1031793","article-title":"Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial.","volume":"171","author":"Bookman","year":"2004","journal-title":"CMAJ"},{"key":"R18-6-20210202","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2474-6-44","article-title":"Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886].","volume":"6","author":"Baer","year":"2005","journal-title":"BMC Musculoskelet Disord"},{"key":"R19-6-20210202","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1001\/archinte.164.18.2017","article-title":"Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial.","volume":"164","author":"Roth","year":"2004","journal-title":"Arch Intern Med"},{"key":"R20-6-20210202","first-page":"2002","article-title":"Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial.","volume":"31","author":"Tugwell","year":"2004","journal-title":"J Rheumatol"},{"key":"R21-6-20210202","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.03.008","article-title":"Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis.","volume":"143","author":"Simon","year":"2009","journal-title":"Pain"},{"key":"R22-6-20210202","first-page":"567","article-title":"Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials.","volume":"33","author":"Towheed","year":"2006","journal-title":"J Rheumatol"},{"key":"R23-6-20210202","first-page":"1841","article-title":"Longterm efficacy of topical nonsteroidal anti-inflammatory drugs in knee osteoarthritis: metaanalysis of randomized placebo controlled clinical trials.","volume":"33","author":"Biswal","year":"2006","journal-title":"J Rheumatol"},{"key":"R24-6-20210202","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1517\/14656566.9.10.1805","article-title":"An alternative topical treatment of osteoarthritis of the knee with cutaneous diclofenac solution.","volume":"9","author":"Ozguney","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R25-6-20210202","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1023\/A:1011961607089","article-title":"In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen.","volume":"15","author":"Hewitt","year":"1998","journal-title":"Pharmacol Res"},{"key":"R26-6-20210202","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2008.08.009","article-title":"All topical NSAIDs are not created equal-understanding topical analgesic drug formulations.","volume":"139","author":"Galer","year":"2008","journal-title":"Pain"},{"issue":"Suppl A","key":"R31-6-20210202","first-page":"3","article-title":"Atlas of individual radiographic features in osteoarthritis.","volume":"3","author":"Altman","year":"1995","journal-title":"Osteoarthritis Cartilage"},{"key":"R32-6-20210202","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke.","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"R34-6-20210202","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/009286159402800112","article-title":"Symptom distress checklists as a component of quality of life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via the physician.","volume":"28","author":"Anderson","year":"1994","journal-title":"Drug Inf J"},{"key":"R35-6-20210202","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3959(99)00267-5","article-title":"Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use.","volume":"85","author":"Tramer","year":"2000","journal-title":"Pain"},{"key":"R36-6-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.311.6996.22","article-title":"Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case control study.","volume":"311","author":"Evans","year":"1995","journal-title":"BMJ"},{"key":"R37-6-20210202","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","article-title":"Cardovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"R38-6-20210202","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjcard.2006.07.069","article-title":"Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.","volume":"99","author":"White","year":"2007","journal-title":"Am J Cardiol"},{"key":"R41-6-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1749-6632.1983.tb47278.x","article-title":"Toxicologic update of dimethyl sulphoxide.","volume":"411","author":"Rubin","year":"1983","journal-title":"Ann N Y Acad Sci"},{"key":"R42-6-20210202","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/2141115a0","article-title":"Dimethyl sulphoxide and lens changes in primates.","volume":"214","author":"Barnett","year":"1967","journal-title":"Nature"},{"key":"R43-6-20210202","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0041-008X(70)90065-7","article-title":"Chronic toxicity of DMSO in primates.","volume":"16","author":"Vogin","year":"1970","journal-title":"Toxicol Appl Pharmacol"},{"key":"R44-6-20210202","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1749-6632.1975.tb25394.x","article-title":"The human toxicology of dimethyl sulfoxide.","volume":"243","author":"Brobyn","year":"1975","journal-title":"Ann N Y Acad Sci"},{"key":"R45-6-20210202","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.1983.tb47285.x","article-title":"Ocular toxicology of dimethyl sulfoxide and effects on retinitis pigmentosa.","volume":"411","author":"Garcia","year":"1983","journal-title":"Ann N Y Acad Sci"},{"key":"R46-6-20210202","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/j.1875-9114.1989.tb04123.x","article-title":"Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma.","volume":"9","author":"Shirley","year":"1989","journal-title":"Pharmacotherapy"},{"key":"R47-6-20210202","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1442-9071.1991.tb00685.x","article-title":"The incidence of progression of lens opacities.","volume":"19","author":"Taylor","year":"1991","journal-title":"Aust N Z J Ophthalmol"},{"key":"R48-6-20210202","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9394(14)76577-8","article-title":"Incidence and progression of cortical, nuclear, and posterior subcapsular cataracts.","volume":"118","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"R49-6-20210202","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0161-6420(97)30043-8","article-title":"Incidence and progression of cortical and posterior subcapsular opacities: the Longitudinal Study of Cataract. The LSC Group.","volume":"104","author":"Leske","year":"1997","journal-title":"Ophthalmol"},{"key":"R50-6-20210202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0161-6420(96)30625-8","article-title":"Incidence and progression of nuclear opacities in the Longitudinal Study of Cataract.","volume":"103","author":"Leske","year":"1996","journal-title":"Ophthalmology"},{"key":"R51-6-20210202","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archopht.116.2.219","article-title":"Incidence of age-related cataract: the Beaver Dam Eye Study.","volume":"116","author":"Klein","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"R52-6-20210202","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002018-200730020-00001","article-title":"Open-label extension studies: do they provide meaningful information on the safety of new drugs?","volume":"30","author":"Day","year":"2007","journal-title":"Drug Safety"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e3181d169b5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:35:38Z","timestamp":1620963338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201011000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181d169b5","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}